<prompt> Which of the following is not a new drug for Migraine?LasmiditanUbrogepantRimegepantRomosozumab  <response>: Option 1 Lasmiditan Highly affinity for 5-HT1Freceptor agonist Acts on trigeminal system without causing vasoconstriction Low affinity for 5-HT1Breceptors Acute therapy for migraine in patients with cardiovascular risk factors Option 2 Ubrogepant Calcitonin gene related peptide CGRP receptor antagonist Acute treatment of migraine attacks Option 3 Rimegepant Only CGRP antagonists that possess oral bioavailability Acute treatment migraine headache Option 4 Romosozumab Sclerostin inhibitor Treatment of osteoporosis in postmenopausal women at high risk for fracture Monoclonal antibodies that antagonize the CGRP pathway are: Galcanezumab Eptinezumab Fremanezumabwhich all target the CGRP peptide Erenumab fully human mAb designed to target the CGRP receptor. Standard migraine Rx involves triptans, but these are CI in patients with pre-existing cardiovascular disease due to their vasoconstrictive propeies. 